Trials / Recruiting
RecruitingNCT05901519
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients on this study will self administer Prednisone for three days before starting Radiation Therapy (RT) and continue to take 60 mg/day during the first three fractions of RT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prednisone | Patients will be treated with PO prednisone, once a day, at a dose of 60 mg/day |
Timeline
- Start date
- 2024-02-16
- Primary completion
- 2026-08-01
- Completion
- 2026-08-01
- First posted
- 2023-06-13
- Last updated
- 2026-03-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05901519. Inclusion in this directory is not an endorsement.